GLP-1 Receptor Agonists
US$ 24.01
glp 1 logo Discover How GLP-1 Trials Are Not One-Size-Fit-All Home | The GLP-1 Source
Description
NEFA, non-esterified fatty acids
Gaeckler et al
Owing to their effectiveness in reducing body weight, once-daily subcutaneous administration of liraglutide 3.0 mg has been approved, and once-weekly subcutaneous administration of semaglutide 2.4 mg is being investigated in phase III trials, for obesity management
Several CVOTs have demonstrated that GLP-1 RAs reduced CV risk in T2DM patients with established ASCVD or high CV risk independent of HbA1c levels
.png?width=2000&height=1200&name=MAPS%20GLP-1%20(1).png)